Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clotrimazole vs Itraconazole in Pityriasis Versicolor
NCT07331792Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Feb 2026
- Primary completion
- May 2026
- Sponsor
- Combined Military Hospital Abbottabad
- Modality
- Orthosteric Ligands
- Conditions
- pityriasis versicolor
01
Overview
Phase 2, randomised trial in pityriasis versicolor comparing 1% Clotrimazole with Itraconazole (2 arms). Primary endpoint: Percentile efficacy at 3 months. Planned start Feb 2026; status: not yet recruiting.
02
Design
2 arms- Study design
- Randomized
1% Clotrimazole
topical 1 % clotrimazole twice daily for 2 weeks
Itraconazole
Oral itraconazole 200mg daily 5 days
03
Who it enrols
Patients aged 15-50 with Pityriasis versicolor, excluding those who used antifungals in the last month, are on immunosuppressants/steroids, are pregnant/lactating, or have chronic conditions like diabetes or hypertension.
04
Endpoints
Primary
Percentile efficacy
Beyond the preview
Go deeper on NCT07331792.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07331792.